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Since the discovery by von Euler (1956) that the substance released from the postganglionic sympathetic nerve was indeed noradrenaline, a vast amount of research has led subsequently to an understanding of some of the physiological processes at the sympathetic nerve ending. The processes whereby the neurotransmitter is synthesized, stored and released, activates specific adrenoceptors located postjunctionally and prejunctionally before its action is terminated by the inactivating mechanisms, have been covered extensively in separate monographs and also compiled in an issue of the British Medical Bulletin, "Catecholamines" (volume 29, 1973) . In the past decade, attention has focused on aspects of prejunctional receptor modulation of transmitter release associated particularly with the cardiovascular and the central nervous systems. It is therefore more appropriate to deal in this review with some of these more recent developments. Where possible, we have attempted to provide the reader with a framework for further reading; this review is not a complete bibliography of this vast subject, but where possible we have cited other reviews and pertinent papers.
Organization of the sympathetic nerve terminal
In the peripheral autonomic nervous system, postganglionic sympathetic nerves have been shown to innervate the majority of the organs of the body, but their cell bodies are situated in prevertebral or para vertebral ganglia. The postganglionic adrenergic innervation is provided by "long adrenergic neurones" to organs such as the heart, blood vessels and glands and by "short adrenergic neurones" which predominantly innervate the urinogenital system. The identification of the terminal varicosities in both the peripheral and central nervous system was greatly assisted by the development of the sensitive fluorescent histochemical methods of Falck and colleagues (1962) , which specifically vis- ualized the axon terminals as beaded strands. Electron microscopy has now revealed a predominance of small granular vesicles within these beaded strands, associated with fewer numbers of large dense cored vesicles.
There is now good evidence that the electrondense granular vesicles correspond to the sites of storage of noradrenaline (Livett, 1973) . The dense core vesicles are reduced in size and number after treatment with drugs such as reserpine, which deplete noradrenaline stores, and are increased by incubation with noradrenaline. A number of other non-granular vesicles are present in the noradrenergic varicosities, but the role played by these remains uncertain. For detailed description of vesicle storage and release of noradrenaline the reader is referred to reviews by Smith (1972 Smith ( , 1973 , and Smith and Winkler(1972) .
Synthesis, storage and release of neurotransmitter
The biosynthesis pathway for noradrenaline has been reviewed by Blaschko (1973) , who is responsible for a great deal of our current knowledge of the synthesis of catecholamines. For the purposes of this review it is sufficient to remind the reader that catecholamines are formed from the essential amino acid L-tyrosine by a series of enzymatic steps. The pathway for transmitter synthesis is shown in figure  1 .
In postganglionic sympathetic fibres, the synthesis pathway stops with noradrenaline; however, in the adrenal medulla where innervation of the chromaffin cells occurs, the pathway continues to form adrenaline. It should be emphasized that both adrenaline and noradrenaline can be released into the blood stream as circulating hormones (see reviews this issue)-probably an underestimated source of circulating noradrenaline. Furthermore, it should be remembered that, in certain neuronal pathways in the central nervous system, the pathway stops with dopamine as the neurotransmitter (Carlsson, 1965; Livett, 1973) and that adrenergic pathways are known also to exist particularly in the brain stem of several species (Fuxe et al., 1975) with adrenaline as the neurotransmitter. These pathways are distinct from the central noradrenergic pathways (Ungerstedt, 1971) .
Large vesicles are transported by a series of microtubules from their source in the Golgi apparatus in the cell body to the terminal varicosities (Smith and Winkler, 1972; Smith, 1973) . Vesicle storage is the means whereby noradrenaline is protected from enzymatic breakdown by monoamine oxidase in the axoplasm. The mechanism whereby noradrenaline is released by nerve impulses has received considerable attention, and the most likely mechanism for this is the process described as exocytosis (Smith and Winkler, 1972; Smith, 1973) which involves the fusion of the vesicle with the neuronal membrane, probably with a rearrangement of phospholipids in the membranes and the subsequent expulsion of the vesicle contents. Noradrenaline is now considered to be stored in the vesicle together with adenosine triphosphate (ATP) in the proportion of approximately 1:4 molecules of catecholarnine and water soluble proteins termed chromogranins. Two proteins, chromogranin A and the enzyme dopamine-/}-hydroxylase, essential for the formation of noradrenaline from dopamine (see previous section), are also released with noradrenaline, whereas the lipids associated with the vesicle membrane are retained. The latter indicates that only the contents, and not the whole vesicle are ejected by exocytosis (Smith, 1973) .
A number of questions remain to be answered relating to the coupling of the excitation of the nerve terminals and the process of release of transmitter; for instance, it is not really known if the action potential invades all the terminals of a given network of varicosities, what stimulus causes the vesicles to migrate towards the neurolemma, or what role is played by the non-granular vesicles (which may represent the storage sites for co-transmitters).
There is now good evidence that the release of transmitter from both chromaffin cells and nerve terminals in the periphery and CNS is particularly sensitive to changes in extracellular Ca 2+ -ion concentration (Smith and Winkler, 1972) . However, 3 H-noradrenaline release, elicited by electrical stimulation or K + ions in brain slices, is particularly resistant to calcium entry blocking drugs, such as verapamil and diltiazem, which act at the level of the voltage-dependent calcium channels in cardiac and vascular smooth muscle (Galzin and Langer, 1983) . The concept of prejunctional modulation of transmitter release is discussed in a subsequent section.
Inactivation mechanisms
Before proceeding to pre-or postjunctional receptor activation following transmitter release, it is appropriate to deal with the processes of inactivation of noradrenaline.
Once released into the synaptic cleft (or neuromuscular junction) the main route of inactivation of noradrenaline is by an active recapture within the nerve terminal described first by Hertting, Axelrod and Whitby (1961) , a process referred to as "neuronal uptake" (Iversen, 1967 (Iversen, , 1971 (Iversen, , 1973 . By this route (which is sensitive to inhibition by cocaine) some 75% of the released noradrenaline is taken up into the terminals. Some noradrenaline is then reincorporated into the small vesicles through a reserpine-sensitive transport, which may occur into either old, or newly formed vesicles (Smith, 1973) . If not reincorporated into vesicle storage, the noradrenaline within the cytosol is subject to meta-bolic breakdown, particularly by monoamine oxidase followed by intraneuronal reduction by aldehyde reductase to DOPEG (3,4-dihydroxyphenylglycol) , which is the main intraneuronal metabolite of noradrenaline in the periphery and the CNS (for review see Langer, 1974a) . Experimental physiologists and pharmacologists utilize this neuronal uptake process to load the transmitter stores with radioactively labelled transmitter, for example 3 Hnoradrenaline. This label can be released subsequently by electrical stimulation, by indirectly acting sympathomimetics, and by potassium depolarization and provides a quantitative assessment of transmitter release. The transporter for noradrenaline in noradrenergic nerve terminals may also be labelled with high affinity with 3 H-desipramine in both the peripheral and the central nervous system (Langer and Raisman, 1983) .
A second route whereby noradrenaline is removed from the synaptic cleft is into the smooth muscle cells. This process is termed extraneuronal uptake (Trendelenburg, 1963; Iversen, 1967; Gillespie, 1973) . The physiological role of this route of elimination has been questioned and debated for nearly two decades. Extraneuronal uptake, unlike neuronal uptake, is very variable between tissues and species, and is much less exacting on the ionic requirements than the neuronal uptake process (Iversen, 1967 (Iversen, ,1973 Gillespie, 1973) . Adrenaline is a preferential substrate for extraneuronal uptake (Iversen, 1971 ) and the widespread distribution of this mechanism, particularly in vascular smooth muscle, makes it a likely candidate for a physiological role, at least in the vasculature. Recently, Henseling (1983) has provided further evidence that 3 H-noradrenaline released from nerve endings in rabbit aorta was subject to extraneuronal uptake and subsequent O-methylation by catechol-O methyl transferase (Trendelenburg, 1963; Gillespie, 1973; Sharman, 1973) particularly in the intimal media of this blood vessel. It has been observed that drugs, such as steroids, which block extraneuronal uptake (Iversen, 1971) or inhibit monoamine oxidase or catechol-O methyl transferase activity, or block both, can potentiate responses to noradrenaline in vitro and influence the route of degradation of 3 Hnoradrenaline (Langer, 1970; Hughes, 1972) . This indicates that, under certain conditions, extraneuronal uptake may play a physiological role in the inactivation of noradrenaline. However, neuronal uptake of noradrenaline represents the major route of inactivation for endogenously released in addition to exogenously administered noradrenaline.
Finally, in recent years, it has been discovered that vasoconstrictor responses in vivo can be mediated by both postsynaptic oti-and ct2-receptors (Drew and Whiting, 1979 ) (see also later section) and it has been shown that postsynaptic <x 2 -receptors, rather than a r receptor-mediated vasoconstrictor responses in vivo are preferentially reduced by adrenalectomy, and restored after replacement with both mineralocorticoids or glucocorticoids (Van Meel, 1982) . The inferences from these findings in relation to hormonal control of postsynaptic a-receptor function warrants further study, since it has been shown that glucocorticoids can inflence the <x 2 -receptor binding of [ 3 H]-clonidine in rat vas deferens in organ culture (Maeda et al., 1983) . These effects have been linked with the regulation or maintenance of the a 2 -receptor proteins in a high affinity state.
Mechanisms controlling neuronal release of noradrenaline
The physiological release of noradrenaline from the terminal varicosities is initiated by the arrival of the action potentials, originating in the cell bodies. It is likely that the action potential causes depolarization in the terminals (Katz and Miledi, 196S; Haefely, 1972) . The excitation-secretion coupling mechanism depends on Ca 2+ ions, but it is probable that the critical area of influence of these ions is at the membrane of the varicosity and the vesicle membrane (Smith and Winkler, 1972) . For a more detailed evaluation of possible mechanisms involved in quantal release of neurotransmitter the reader is referred to some recent papers (Alberts, Bartfai and Stjarne, 1981; Blakeley, Cunnane and Petersen, 1981; Cunnane and Stjarne, 1982) which deal with recent electrophysiological evidence on the process of release from noradrenergic varicosities.
The release of noradrenaline by indirectly acting sympathomimetic amines such as tyramine is different from that evoked by nerve stimulation (Trendelenburg, 1972) . Thus tyramine-induced release is not dependent on extracellular Ca 2+ (Smith and Winkler, 1972) , and is not blocked by tetrodotoxin (Bell, 1968) . In addition, the release of noradrenaline by tyramine is likely to involve stores of the transmitter different from those acted upon by nerve stimulation (Furchgott and Garcia, 1968) . Finally, the effects of tyramine are prevented by inhibition of neuronal uptake with cocaine or desip-ramine, proving that tyramine is a substrate for the transporter of noradrenaline in noradrenergic nerve terminals.
Prejunctional modulation of noradrenaline release
It is now clear that the terminal varicosities of the sympathetic nerves can no longer be considered as mere sites for synthesis, storage, release and inactivation of the transmitter. Some 25 years ago the experiments of Brown and Gillespie (1957) showed that an a-adrenoceptor blocking drug,phenoxybenzamine, enhanced the overflow of 'H-noradrenaline from the perfused cat spleen yet, because of the array of pharmacological properties of this drug, it was some years later that this effect was linked with a possible antagonist action of phenoxybenzamine at prejunctional a-adrenoceptors (Langer, 1974b; Gillespie, 1980) . Since the known inhibitors of neuronal uptake, for example cocaine or desipramine, failed to augment the release of noradrenaline elicited by nerve stimulation (Blakeley, Brown and Ferry, 1963; Langer and Enero, 1974) it was clear that the facilitation of release by a-adrenoceptor antagonists such as phenoxybenzamine was not a result of inhibition of neuronal uptake. The mechanisms involved in prejunctional modulation of transmitter release have received a great deal of attention in the past decade (see reviews : Langer, 1974b : Langer, , 1977 : Langer, , 1981a Starke, 1977 Starke, , 1981 Westfall, 1977; Gillespie, 1980; Rand, McCulloch and Story, 1980; Langer, Massingham and Cavero, 1980; Lokhandwala and Eikenburg, 1983) .
The predominant prejunctional receptor system in the periphery is the <x 2 -receptor, and it has been identified in most tissues from the majority of species examined. In addition, a 2 -receptors are located anatomically on non-neuronal structures such as glands and muscles (see later section). These can now be clearly differentiated pharmacologically from the ^-receptor subtype (table I shows the location and function of the a r and 012-subtypes of adrenoceptors). A schematic representation of the peripheral noradrenergic neuroeffector junction is shown in figure 2 , where the location of the a-and f}-adrenoceptor subtypes is represented. Recent studies of <x 2 -receptors have shown that compounds with considerably different chemical structures (imidazolines, phenylethylamines and aminotetralins) are intrinsically active as agonists at 012-receptor sites to inhibit transmitter release, end-organ responses or both (Langer, 1981a; Timmermans and Van Zwieten, 1982) . Within the CNS, the concepts of prejunctional modulation of neurotransmission attain considerable complexity since a^receptors are located on prejunctional noradrencrgic terminals in addition to prejunctional 5-HT terminals. While "autoinhibition" of noradrenaline release is probably the major role of prejunctional a 2 -receptor in the periphery, in the CNS the concept of "lateral inhibition" (the inhibition of release of one neurotransmitter through prejunctional-receptor activation by a second transmitter) is now well demonstrated (Starke, 1977) . Negative feedback of transmitter release necessitates the stimulation of prejunctional receptors by the transmitter on the nerve terminals from which it is released. Yet, although inhibition of release of other transmitters, such as 5-HT, by stimulation of ot 2 -receptors located on the 5-HT nerve terminals is well known, it is not possible to facilitate the-release of ^H-S-HT by blocking <x 2 -receptors. Thus these inhibitory a 2 -receptors are present on the 5-HT-terminals and they may be activated pharmacologically by <x 2 -adrenoceptor agonists, but their physiological activation by noradrenaline released from an adjacent terminal cannot yet be demonstrated (Galzin, Moret and Langer, 1984) .
In order to explore further these modulating mechanisms, it is essential to increase the sensitivity of the methods of quantifying transmitter release. One such method involves the measurement of endogenous release of transmitter by HPLC and electrochemical detection, rather than measurement of 3 H-labelled transmitter. Furthermore, from a pharmacological standpoint our understanding of receptors has been advanced by the introduction of receptor binding techniques which provide valuable insight into the specific drug -receptor interaction in isolation. However, it should not be forgotten that such isolation from both "input" and "output" may impose unknown characteristics on the receptor proteins. For an interesting debate on this issue the reader is referred to McGrath (1983) and U'Prichard (1983) .
By comparison with the CNS, the innervation of peripheral tissues is perhaps less complex, and yet, it is known that a-receptors of the a 2 -subtype are found prejunctionally to cholinergic innervation in the intestine (Paton and Vizi, 1969; Drew, 1978) and these findings have been exploited pharmacologically. Second, a number of recent reports indicate that co-transmitter substances may also be released with noradrenaline. Such a system probably occurs in the vas deferens (Sneddon, Westfall and Fedan, 1982) and the release of peptides such as VIP from some cerebral vessels has also been suggested. The exact role of co-transmitters on noradrenergic transmission remains to be established, but a system of this type may be responsible for some of the extrajunctional potential (eJP) recordings, which prove so difficult to antagonize pharmacologically (Hirst and Neild, 1980,1981) .
Prejunctional modulation: inhibition
The prejunctional inhibition of noradrenaline release by activation of prejunctional <X2-receptors operates for the Ca 2+ -dependent exocytotic release induced by electrical or by K + -induced depolarization (Langer, 1977 (Langer, ,1981a Starke, 1977; Westfall, 1977; Gillespie, 1980) . One possible mechanism of <x 2 -receptor mediated inhibition involves a reduction in the availability of Ca 2+ -ions for excitation -secretion coupling and exocytotic release. A major characteristic of the negative feedback mechanism is that it is most effective at inhibiting noradrenaline output when nerves are stimulated at low or intermediate frequencies and less effective at high frequency. oc-Receptor antagonists only increase transmitter release when the pulse interval is sufficiently close to allow build up of noradrenaline in the synaptic cleft. However, this point has been debated recently (Angus and Korner, 1980; Langer, 1981b; Story et al., 1981; Kalsner, 1983) and is discussed in the following section.
An important concept of receptor-mediated inhibition involves the prevention of spread of depolarization through the network of varicosities as suggested by Stjarne (1978) , Alberts, Bartfai and Stjarne (1981) and Cunnane and Stjarne (1982) . Although Ca 2+ -flux mechanisms are clearly important in the inhibition of noradrenaline release by <X2-receptor activation, Ca 2+ -sensitive changes in cyclic nucleotidc formation are also involved in some systems (O'Dea and Zatz, 1976; Pelayo, Dubocovich and Langer, 1978) . In addition, there is evidence that catecholamines are able to activate Na + -K + -ATPase activity in brain synaptosomes (Yoshimura, 1973; Gilbert, Wyllie and Davison, 1975) and adrenal medulla (Gutman and Boonyaviroj, 1977) and it has been postulated that, when the enzyme Na + -K + -ATPase is activated, transmitter release is inhibited. Undoubtedly at the molecular level, the exact mechanisms involved in the inhibition of transmitter release through activation of prejunctional a 2 -adrenoceptors remain to be elucidated.
Other inhibitory receptor systems modulating noradrenaline release
It is now well known that a variety of receptors are located on some sympathetic nerve terminals which, when stimulated, inhibit release of noradrenaline, although their physiological role is not yet clear. Amongst the most studied are the muscarinic receptors on the innervation of the heart (Loffelholz and Muscholl, 1970; Fozard and Muscholl, 1972) . In this tissue they may play a physiological role (Muscholl, 1979 (Muscholl, , 1980 , since both cholinergic and noradrenergic pathways innervate cardiac muscle cells, and their close proximity makes it very likely that the muscarinic receptors on the sympathetic terminals are activated by acetylcholine released from the vagus.
The presence of prejunctional inhibitory dopamine receptors modulating noradrenergic transmission was first reported in the perfused cat spleen (Langer, 1973) and cat nictitating membrane (Enero and Langer, 1975) and this has been extended to several isolated blood vessels in vitro (Hope et al., 1977; O'Connor and Brown, 1982) . It has also been shown that dopamine receptor agonists reduce end organ responses in vivo during sympathetic nerve stimulation (Long et al., 1975; Massingham, Dubocovich and Langer, 1980) . The prejunctional dopamine receptors (DA 2 ) may now be differentiated clearly from the DAi-receptor subtypes which mediate vasodilation in certain vascular beds (Goldberg, Volkman and Kohli, 1978; Brodde, 1982) . Selective antagonists for DA 2 -receptors include S-sulpiride (O'Connor and Brown, 1982) and for the DAi-receptor, SCH23390 (Iorio et al., 1983) . Neuronal DA-receptors are clearly the site of action for agonists such as N,N-di-n-propyl dopamine or pergolide which reduce arterial pressure and heart rate in the intact animal (Massingham, Dubocovich and Langer, 1980; Cavero, Lefevre-Borg and Gomeni, 1981) . For a recent review on dopamine receptors in the CNS and in the cardiovascular system the reader is referred to Seeman (1981) and Cavero, Massingham and Lefevre-Borg (1982) , respectively.
A third inhibitory mechanism involves prostaglanHins. PGE 2 has been the most widely studied prostanoid and has been demonstrated, in many tissues, to inhibit noradrenaline release (Horten, 1973; Hedqvist, 1974; Armstrong, 1980) . It is likely that the stimulus for the local release of prostaglandin is related to the postjunctional receptor activation by noradrenaline; the PG formed would therefore have to cross the synaptic cleft to exert an inhibitory action on noradrenaline release prejunctionally. Once again the physiological role of prostaglandin-mediated inhibition is debated, since other products of the cyclooxygenase pathway particularly, PGI 2 (prostacycUn), are preferentially formed in this cascade, but are considerably less potent at inhibiting noradrenaline-release, particularly in vivo. Little is known about the thromboxane (TXA) pathway in this respect, although the stable endoperoxide U46619 which is a direct TXA 2 -agonist receptor (Coleman et al., 1981) failed to modify the "twitch response" of the rat vas def erens, a preparation in which both <x 2 -receptor and PGE2-mediated inhibition of motor transmission occurs (Hicks and Langer, unpublished observations) .
Finally, adcnosine and adenine nucleotides have been found to inhibit noradrenergic-transmission in several species and tissues (Burnstock, 1980) . As mentioned in a previous section, the possible cotransmitter role of ATP or a related purine, at least in some tissues, adds support to a purinergic inhibitory mechanism. Similarly, a physiological role for various peptides has been raised recently. To date inhibitory opiate receptors for adrenergic transmission in the periphery remain restricted, for example to the mouse vas deferens (Henderson and Hughes, 1976) and the cat nictitating membrane (Dubocovich and Langer, 1980) .
Prejunctional modulation: facilitation of noradrenaline release
In its simple form, the autoregulation theory of transmitter release dictates that, as the synaptic concentrations of the transmitter increases, autoinhibition occurs (see previous section). In physiological terms there must presumably be a mechanism to restart the release of transmitter subsequent to autoinhibition or inhibition of release by activation of some other inhibitory receptor system. It is on this issue that ncurophysiological and pharmacologically derived data are in greatest conflict (Starke, 1981; Kalsner, 1983) . The effectiveness of (preceptor antagonists to enhance the release of noradrenaline is dependent on there being sufficient concentration of noradrenaline in the synaptic cleft to stimulate prejunctional a-adrenoceptors (Cubeddu and Weiner, 1975; Story et al., 1981) , and the factors controlling this parameter are clearly the frequency of stimulation and the pulse duration (McCulloch, Rand and Story, 1972) . In the vas deferens of several species, single pulse stimulation releases noradrenaline, this release may be reduced by exogenous addition of a 2 -rcccptor agonists, for example clonidine, but not augmented by selective otz-receptor antagonists (Marshall, 1983) .
A well established electrophysiological approach is to measure excitatory junctional potentials (eJP) from a postjunctional site in response to application of a fixed stimulus to the prejunctional nerve (Blakeley, Cunnane and Petersen, 1981; Stjarne, 1981; Cunnane and Stjarne, 1982) . The frequency and amplitude of the eJP are assumed to reflect the quantal release of transmitter from one or more closely related sites on the varicosity. Some evidence has been presented, using these techniques, to suggest that the reduction of the quantal release of transmitter by <x 2 -receptor agonists and the facilitation of release by ot2-receptor antagonists may not always be mediated from the same site on the varicosities (Alberts, Bartfai and Stjarne, 1981; Blakeley, Cunnane and Peterson, 1981; Kuriyama and Makita, 1983) . Unfortunately, since most of this information has been derived in vas deferens of several species, in which the neurotransmission process is clearly not just noradrenergic (see previous section) it remains to be established whether these critical findings relate absolutely to sympathetic transmission, or may be explained by a modulating effect of ATP or related purines on the noradrenergic system (Kazic and Milosarljeric, 1980; Sneddon, Westfall and Fedan, 1982) .
A second point for consideration in experiments on ot-receptor autoregulation of noradrenaline release relates to the use of uptake blocking drugs. If the theory of presynaptic modulation of transmitter release is so dependent on the synaptic concentration of noradrenaline, it is crucial to control the main route of inactivation of noradrenaline, particularly if the inhibitory actions of catecholamines are being studied. The relationship between inhibitors of neuronal uptake, and transmitter release has been the subject of some recent studies in the CNS (Pelayo, Dubocovich and Langer, 1978; Gothert, Schlicker and Kostermann, 1983) and in peripheral systems (Langer and Dubocovich, 1981) . Third, from a pharmacological standpoint, agonist and antagonists should be demonstrated to exert concentration-dependent inhibition or facilitation of transmitter release. Progressively, with the finding of more potent, selective and competitive antagonists of a 2 -receptors, this is being demonstrated. However, by the nature of this competitive antagonism the absolute degree of facilitation observed during autoregulation will depend on the competition between concentration of released transmitter in the synapse and the antagonist. This is probably most important when considering the effect of these drugs on in vivo systems in intact animals (Majewski, Hedler and Starke, 1983) where reflex activity will also be evident.
In particular, two other receptor-mediated mechanisms which facilitate the release of noradrenaline should be mentioned, both of which concern the cardiovascular system. Recent evidence suggest that very low concentrations of adrenaline augment the release of noradrenaline at many sympathetic nerve terminals. It is now thought that this effect is mediated by prejunctional 0-receptors (Rand, McCulloch and Story, 1980; Majewski, Tung and Rand, 1982) . The presence of prejunctional facilitatory 0-receptors was first reported by Adler-Graschinsky and Langer (1974, 1975) . Isoprenaline was clearly shown to augment noradrcnaline release, but the antagonist actions of 0-blocking drugs never provided the conclusive evidence that this pathway operated physiologically (Adler-Graschinsky and Langer, 1975) . The finding that adrenaline may preferentially activate those prejunctional 0-receptors (Rand et al., 1979 ) is of particular relevance in relation to the pathogenesis of some forms of hypertension and may be most relevant during stress. It is likely that adrenaline is first taken up by the sympathetic neurone, then released to activate the prejunctional facilitatory 0-receptors. The consensus of pharmacological opinion favours a /^receptor subtype mediating this effect, but it remains to be established whether the clinical efficacy of the /5-adrenoceptor blocking drugs in hypertension relates to blockade of presynaptic facilitatory 0-adrenoceptors (Langer, 1976; Misu and Kubo, 1983) .
A second facilitatory mechanism at the sympathetic nerve ending involves angiotensin (see detailed consideration in Westfall, 1977; Lokhandwala and Eikenburg, 1983) . Again, the earlier findings on this facilitatory mechism have been given credence by the discovery that the angiotensin converting enzyme inhibitors, exemplified by captopril (Antonaccio and Kerwin, 1981; Clough et al., 1982) prevent An-induced facilitation of noradrenaline release.
For consideration of cholinergic nicotinicreceptor mediated facilitation the reader is referred to Starke (1977) , Westfall (1977) and Gillespie (1980) and for the presynaptic actions of 5-hydroxytryptamine and histamine, to McGrath (.1977) and McGrath and Shepherd (1978) .
The posuynaptic adrenocepton
The purpose of the release of noradrenaline at the sympathetic junction is to provide the stimulus for depolarization in the postjunctional membrane. The subject of postjunctional adrenoceptor activation has also received much attention in the past few years following the discovery that two subtypes of a-adrenoceptors could be clearly characterized (table I) . It was recently reported that the aadrenoceptor blocking drug prazosin was considerably less effective against vasoconstrictor responses induced by noradrenaline in vivo, while a potent competitive antagonist effect could be demonstrated against known a r receptor agonists, for example phenylephrine (Drew and Whiting, 1979) . The following reviews will provide the reader with an extended bibliography in this area (Timmermans and Van Zwieten, 1981, 1982; Langer and Shepperson, 1982a,b; McGrath, 1982) ; for a more general review of neuroeffector interaction in the blood vessel wall see Vanhoutte, Verbeunen and Webb (1981) . It is now clear that both o<i-and <x 2 -adrenoceptors exist postjunctionally and drugs such as yohimbine, which facilitate the release of noradrenaline prejunctionally also competitively antagonize vasoconstrictor responses induced by <x 2 -receptor agonists postsynaptically (see previous reviews). Despite the presence of postsynaptic a 2 -receptors in vivo it is apparent that the predominant noradrenergic innervation in the cardiovascular system is through ar receptors (Langer, Massingham and Shepperson, 1980; Langer and Shepperson, 1982b) , although there may be differences between various vascular beds and non-vascular smooth muscle. In pathological states such as hypertension, some evidence has now been obtained in vitro in tail arteries of the spontaneously hypertensive rat (SHR) that postsynaptic a 2 -receptors are also stimulated by neurally released noradrenaline (Hicks, Medgett and Langer, 1984) and this does not appear to be the case in normotensive controls. The possibility that prejunctional <x 2 -receptor mechanisms are also altered in hypertension has been reviewed recently (Lokhandwala and Eikenburg, 1983) . The in vivo and in vitro findings have led to a tentative anatomical description of "junctional" or "extrajunctional" location of a-receptor subtypes in vascular smooth muscle (Langer and Shepperson, 1982a ). An extrajunctional or intraluminal location of <x 2 -receptors would make them more readily accessible to circulating catecholamines ( fig. 2 ).
In considering "junctional" adrenoceptor subtypes, Hirst and Neild (1980, 1981) have provided some electrophysiological data on the excitatory junction potentials (eJP) recorded in arteriolar smooth muscle after the application of low pulse stimulation to the prejunctional nerve plexus (see also Illes, 1983) . These eJP were totally resistant to blockade with known <Xr or a 2 -receptor antagonists, but the iontophoretic application of noradrenalinemediated eJP were sensitive to a-receptor blocking drugs. Since there is as yet no antagonist of these eJP, it is premature to ascribe these effects to a new subtype of adrenoceptors. The arguments that the PHYSIOLOGY OF THE SYMPATHETIC NERVE ENDING . 697 a-adrenoceptor antagonists cannot gain access or cannot attain a sufficiently high local concentration at the receptor site to block the "transmitter" effect (Hirst and Neild, 1980,1981) are perhaps less pharmacologically sound. Therefore the most tenable explanation to date for these findings is that of co-transmitter release being responsible for generation of these eJP.
It remains to be established if prejunctional and postjunctional <x 2 -receptors are pharmacologically identical. They have different anatomical location, and subserve different functions, but to date there is limited pharmacological evidence to distinguish them (Hicks, 1981) ; furthermore, it remains to be established if they provide a physiological capacity. Since a 2 -receptor-mediated vasoconstriction is exquisitely sensitive to antagonists of the voltage dependent Ca 2+ -channel particularly in vivo (Cavero et al., 1983) , it remains an interesting possibility that their main role may be to regulate membrane potential (Hicks, 1983) .
CONCLUSIONS
Our understanding of the physiology of the sympathetic nerve ending has advanced significantly in the past 2 S years, and much has been established in the field of synthesis and storage of transmitter. However, the exact physiological role of prejunctional receptor modulation will undoubtedly remain controversial, despite the demonstration of the appropriate receptor systems on sympathetic nerve terminals. Of physiological relevance is the evidence that low concentrations of sympathomimctics and others "autocoids" can modulate sympathetic neurotransmission and that pharmacological modulation of transmitter release is always most effective during low frequency nerve stimulation. Clearly, the influence of drugs in this system will depend on their relative selectivity at these sites of modulation.
